menu

CME: Novel Therapies to Manage OFF Episodes in Patients with Parkinson’s Disease

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Novel Therapies to Manage OFF Episodes in Patients with Parkinson’s Disease

close
0.50 credits
30 minutes
Novel Therapies to Manage OFF Episodes in Patients with Parkinson’s Disease
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Comments
  • Overview

    This Expert Exchange activity is designed to make clinicians aware of the potential for emerging pharmacotherapies in treating patients with Parkinson’s disease.

  • Target Audience

    This activity has been designed to meet the educational needs of health care professionals involved in the treatment of patients with Parkinson’s disease.

  • Educational Objectives

    Upon completion of this activity, participants will be better able to do the following:

    • Evaluate the benefits and limitations of existing pharmacotherapies for reducing off episodes in patients with Parkinson’s disease.
    • Identify patient scenarios where emerging pharmacotherapies may be beneficial in reducing off episodes in patients with Parkinson’s disease.
    • Identify common adverse effects associated with emerging pharmacotherapies, as well as strategies for preventing/mitigating them.
  • Financial Support

    This activity has been supported by an independent educational grant from Sunovion Pharmaceuticals Inc. and Kyowa Kirin, Inc.

  • Providers

    Jointly provided by the University of Florida College of Medicine and Novus Medical Education.

  • Joint Accreditation Statement

     This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Florida College of Medicine and Novus Medical Education. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

  • Physician Continuing Medical Education

    The University of Florida College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclosure of Conflicts of Interest

    The University of Florida College of Medicine requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to UF COM policy. The UF COM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Dr. Hauser has received personal compensation for consulting, serving on a scientific advisory board, speaking or financial interests from: Acadia Pharmaceuticals, Acorda Therapeutics, Adamas Pharmaceuticals, Affiris, Alphasights, Amneal Pharmaceuticals Inc., Aranca, Axial Biotherapeutics, Axovant Sciences, Brittannia Pharmaceuticals, Ltd., Cadent Therapeutics, Cerespir Inc., CNS Ratings LLC, Defined Health, Denali Therapeutics, Enterin Inc., Extera Partners, F. Hoffman-La Roche Ltd., Gerson Lehrman Group, Guidepoint Global, lmpax Laboratories, Impel Neuropharma, lnhibikase, International Stem Cell Corp., Kaiser, Kyowa Kirin, Kashiv Pharma LLC, L.E.K. Consulting, Lundbeck, Lundbeck A/S, Mitsubishi Tanabe Pharmaceuticals, Neuro Challenge Foundation for Parkinson's, Neurocrine Biosciences, Neuroderm, Pennside Partners, Perception OpCo, Scion Neurostim LLC, Seelos Therapeutics, Slingshot Insights, Sunovion Pharmaceuticals Inc, Teva Pharmaceuticals and USWorldMeds Dr. Hauser has received grant/research support from: AbbVie Inc, Acorda Therapeutics, AstraZeneca, Axovant Sciences, Cavion, Centogene, Cerevance, Cerevel, Covance, Enterin Inc., F. Hoffman-La Roche, Global Kinetics Corp., Impax Laboratories, Intec Pharma Ltd., Jazz Pharmaceuticals, Lundbeck, Neuroderm, Neuraly, Pharma2B, Revance Therapeutics Inc. and Sunovion Pharmaceuticals.

    Dr. Isaacson has received research support and/or personal compensation for consulting, serving on a scientific board, speaking or financial interests from: Abbvie, Acadia, Acorda Therapeutics, Adamas, Addex, Affiris, Alexva, Allergan, Amarantus, Amneal Pharmaceuticals, Aptinyx, Axial, Axovant Sciences, Benevolent, Biogen, Britannia Pharmaceuticals, Cadent, Cala, Cerecor, Cerevel, Cipla, Eli Lilly, Enterin, GE Healthcare, Global Kinetics, Impax Laboratories, Impel Neuropharma, Intec Pharma Ltd., Ipsen, Jazz Pharmaceuticals, Kyowa Kirin, Lundbeck, Merz, Mitsubishi Tanabe, Neuralys, Neurocrine Biosciences, Neuroderm, Pharma2B, Prilenia, Promentis, Revance, Roche, Sanofi, Sunovion, Sun Pharma, Teva Pharmaceuticals, Theravance, UCB, US World Meds and Zambon.

    Planners and Managers
    The UF COM – including Activity Director Aparna Wagle Shukla, MD – and Novus Medical Education planners and managers have no financial relationships to disclose.

  • Method of Participation

    There are no fees for participating and receiving CME credit for this activity. To claim credit, participants must complete the following:

    1. Read the educational objectives, accreditation information and faculty disclosures at the beginning of this activity.
    2. Complete the pre-test.
    3. View the activity.
    4. Complete the post-test and evaluation.
    5. Physicians who receive a grade of 80% or better on the post-test and complete the evaluation will receive a CME certificate.
    6. All other participants who receive a grade of 80% or better on the post-test and complete the evaluation will receive a Certificate of Participation.
  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • CME Provider

    The University of Florida College of Medicine can be contacted at: cme-mail@ufl.edu or 352-733-0064.

  • CME Inquiries

    For all CME certification inquiries, please contact ReachMD at: info@reachmd.com.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    This Expert Exchange activity is designed to make clinicians aware of the potential for emerging pharmacotherapies in treating patients with Parkinson’s disease.

  • Target Audience

    This activity has been designed to meet the educational needs of health care professionals involved in the treatment of patients with Parkinson’s disease.

  • Educational Objectives

    Upon completion of this activity, participants will be better able to do the following:

    • Evaluate the benefits and limitations of existing pharmacotherapies for reducing off episodes in patients with Parkinson’s disease.
    • Identify patient scenarios where emerging pharmacotherapies may be beneficial in reducing off episodes in patients with Parkinson’s disease.
    • Identify common adverse effects associated with emerging pharmacotherapies, as well as strategies for preventing/mitigating them.
  • Financial Support

    This activity has been supported by an independent educational grant from Sunovion Pharmaceuticals Inc. and Kyowa Kirin, Inc.

  • Providers

    Jointly provided by the University of Florida College of Medicine and Novus Medical Education.

  • Joint Accreditation Statement

     This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Florida College of Medicine and Novus Medical Education. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

  • Physician Continuing Medical Education

    The University of Florida College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclosure of Conflicts of Interest

    The University of Florida College of Medicine requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to UF COM policy. The UF COM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Dr. Hauser has received personal compensation for consulting, serving on a scientific advisory board, speaking or financial interests from: Acadia Pharmaceuticals, Acorda Therapeutics, Adamas Pharmaceuticals, Affiris, Alphasights, Amneal Pharmaceuticals Inc., Aranca, Axial Biotherapeutics, Axovant Sciences, Brittannia Pharmaceuticals, Ltd., Cadent Therapeutics, Cerespir Inc., CNS Ratings LLC, Defined Health, Denali Therapeutics, Enterin Inc., Extera Partners, F. Hoffman-La Roche Ltd., Gerson Lehrman Group, Guidepoint Global, lmpax Laboratories, Impel Neuropharma, lnhibikase, International Stem Cell Corp., Kaiser, Kyowa Kirin, Kashiv Pharma LLC, L.E.K. Consulting, Lundbeck, Lundbeck A/S, Mitsubishi Tanabe Pharmaceuticals, Neuro Challenge Foundation for Parkinson's, Neurocrine Biosciences, Neuroderm, Pennside Partners, Perception OpCo, Scion Neurostim LLC, Seelos Therapeutics, Slingshot Insights, Sunovion Pharmaceuticals Inc, Teva Pharmaceuticals and USWorldMeds Dr. Hauser has received grant/research support from: AbbVie Inc, Acorda Therapeutics, AstraZeneca, Axovant Sciences, Cavion, Centogene, Cerevance, Cerevel, Covance, Enterin Inc., F. Hoffman-La Roche, Global Kinetics Corp., Impax Laboratories, Intec Pharma Ltd., Jazz Pharmaceuticals, Lundbeck, Neuroderm, Neuraly, Pharma2B, Revance Therapeutics Inc. and Sunovion Pharmaceuticals.

    Dr. Isaacson has received research support and/or personal compensation for consulting, serving on a scientific board, speaking or financial interests from: Abbvie, Acadia, Acorda Therapeutics, Adamas, Addex, Affiris, Alexva, Allergan, Amarantus, Amneal Pharmaceuticals, Aptinyx, Axial, Axovant Sciences, Benevolent, Biogen, Britannia Pharmaceuticals, Cadent, Cala, Cerecor, Cerevel, Cipla, Eli Lilly, Enterin, GE Healthcare, Global Kinetics, Impax Laboratories, Impel Neuropharma, Intec Pharma Ltd., Ipsen, Jazz Pharmaceuticals, Kyowa Kirin, Lundbeck, Merz, Mitsubishi Tanabe, Neuralys, Neurocrine Biosciences, Neuroderm, Pharma2B, Prilenia, Promentis, Revance, Roche, Sanofi, Sunovion, Sun Pharma, Teva Pharmaceuticals, Theravance, UCB, US World Meds and Zambon.

    Planners and Managers
    The UF COM – including Activity Director Aparna Wagle Shukla, MD – and Novus Medical Education planners and managers have no financial relationships to disclose.

  • Method of Participation

    There are no fees for participating and receiving CME credit for this activity. To claim credit, participants must complete the following:

    1. Read the educational objectives, accreditation information and faculty disclosures at the beginning of this activity.
    2. Complete the pre-test.
    3. View the activity.
    4. Complete the post-test and evaluation.
    5. Physicians who receive a grade of 80% or better on the post-test and complete the evaluation will receive a CME certificate.
    6. All other participants who receive a grade of 80% or better on the post-test and complete the evaluation will receive a Certificate of Participation.
  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • CME Provider

    The University of Florida College of Medicine can be contacted at: cme-mail@ufl.edu or 352-733-0064.

  • CME Inquiries

    For all CME certification inquiries, please contact ReachMD at: info@reachmd.com.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 10/22/20